Spotlight Returns To Biogen R&D To Sustain Success
Executive Summary
After an impressive commercial run for Biogen Idec, with four drug launches in two years, it’s up to R&D to deliver more innovative medicines. The bar is high in the areas of neurology Biogen is exploring; Chief Medical Officer Alfred Sandrock discussed the company’s R&D momentum in a recent interview.
You may also be interested in...
Biogen Anti-LINGO MS Study Failure Removes Upside
Biogen’s potential game-changing multiple sclerosis drug anti-LINGO-1 failed to meet the primary or secondary endpoints of a Phase II study, highlighting the challenges the biotech faces developing treatments for serious CNS disorders.
Deal Watch: Anacor Purchase Marks Pfizer's Post-Allergan Bolt-On Strategy
Celgene pays Agios $200m up front for collaboration in immuno-oncology. Biogen inks pacts with Regenxbio and Penn to apply AAV technology to its developing gene-therapy program.
Biogen Expands Gene Therapy Efforts Via Deals With Regenxbio, Penn
Biotech gets AAV technology license from Regenx for use in developing therapeutics for rare genetic eye disorders, which will be developed in tandem with University of Pennsylvania researchers.